BioSenic Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	2.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

BioSenic CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bernard Malissen	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jean-François Bach	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Yves Sagot	Independent Director	1.8yrs	Veri yok	Veri yok
Alain Fischer	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jean-Luc Vandebroek	Non-Executive Director	2.1yrs	Veri yok	Veri yok
Jean-François Rax	Non-Executive Director	2.1yrs	Veri yok	Veri yok
Jules Hoffmann	Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Carlo Chizzolini	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Frédéric Houssiau	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Revital Rattenbach	Independent Director	2.1yrs	Veri yok	Veri yok
Jean Stephenne	Independent Director	2.1yrs	Veri yok	Veri yok

2.1yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: BT1 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.1 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

BioSenic Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

BioSenic S.A. Announces Executive Changes

Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO

Biosenic S.A. and Its Subsidiary Medsenic SAS Announces the Promotion of Carole Nicco to Chief Operating Officer

BioSenic S.A. Appoints Yves Sagot as Independent Director

BioSenic Appoints Dr. Carole Nicco as Chief Scientific Officer

BioSenic S.A. Appoints Michel Wurm as Interim Chief Medical Officer

Recent updates

BioSenic S.A. Announces Executive Changes

Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO

Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office

Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide (Ato) Targeting Cgvhd

New major risk - Shareholder dilution

BioSenic S.A. to Report Fiscal Year 2023 Results on Jun 06, 2024

Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease

BioSenic S.A. Patent Granted in Canada for Broader Protection of ATO Therapeutic Platform

BioSenic Presents New Phase 3 Data on JTA-004 to Treat Severe Osteoarthritis Pain at the 2024 OARSI World Congress

BioSenic Files for Additional Patent Protection Following New Clinical Evidence of Efficacy for JTA-004 in OA

Biosenic S.A. and Its Subsidiary Medsenic SAS Announces the Promotion of Carole Nicco to Chief Operating Officer

New major risk - Market cap size

BioSenic S.A. Performs Further Analysis of Its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide in cGvHD

BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Treatment Supporting Clinical Trial for Systemic Sclerosis

New major risk - Market cap size

BioSenic S.A. Puts Phase IIb Allob Trial on Hold

BioSenic S.A. Appoints Yves Sagot as Independent Director

BioSenic Appoints Dr. Carole Nicco as Chief Scientific Officer

BioSenic S.A. Appoints Michel Wurm as Interim Chief Medical Officer

Less than half of directors are independent

BioSenic SA provides update on its autoimmune disease platform based on ATO (arsenic trioxide)

Less than half of directors are independent

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi